Met-097i
Metsera公布MET-097i IIb期顶线数据，辉瑞73亿美元收购加速全球III期临床启动
Metsera发布超长效GLP-1候选药MET-097i在VESPER-1和VESPER-3 IIb期临床数据：28周注射最高体重下降14.1%，耐受性良好。VESPER-1总中断率仅2.9%。基于此，全球III期临床将于2025年底启动，同时支撑辉瑞73亿美元收购布局。
GLP-1
Met-097i
Pfizer’s $7.3B Obesity Gamble Pays Early with MET-097i Phase 2b Success
Pfizer’s $7.3 billion acquisition of Metsera is backed by new Phase 2b data for MET-097i, an ultra-long-acting GLP-1 candidate showing 14% weight loss and promising tolerability. Phase 3 initiation is slated for late 2025. Monthly dosing could give Pfizer an edge in the obesity race.
NewCo Model
China-Origin Assets Exclusively Fuel New US and UK Biotech Startups (2023–2025)
Analysis of US and UK biotech startups operating under the NewCo model, built solely on China-licensed assets. Includes executive summary, company list, trends, and risks.
歌礼制药
歌礼ASC47联合司美格鲁肽减重提升56.2%，显著改善胃肠耐受性
歌礼制药公布ASC47-103研究顶线结果：ASC47联合司美格鲁肽在肥胖患者中较单药减重效果提升高达56.2%，并降低LDL-C，改善胃肠耐受性，停药后反弹更轻。
Ascletis Pharma
Ascletis’ ASC47 Combo with Semaglutide Shows 56% Greater Weight Loss, Better GI Safety
Ascletis Pharma reported topline results from its ASC47-103 study in obesity: ASC47 plus semaglutide enhanced weight loss by up to 56.2% versus semaglutide alone, reduced LDL-C, improved GI tolerability, and showed reduced rebound post-treatment.
Metsera
辉瑞73亿美元收购Metsera，布局潜在月度给药的新一代减肥疗法
辉瑞 ($PFE) 宣布将收购 Metsera ($MTRS)，交易总价值最高达 73 亿美元，获得其核心资产 MET-097i，这是一款新一代 GLP-1 受体激动剂，超长效、可潜在月度给药，12 周体重下降可达 11.3%，耐受性良好。
HRS9531
Hengrui’s HRS9531 NDA Accepted in China, First Homegrown GLP-1/GIP Dual Agonist to Challenge Tirzepatide
Hengrui’s HRS9531 NDA is accepted in China, marking the first homegrown GLP-1/GIP dual agonist for obesity. Clinical data shows strong weight loss and safety, challenging Eli Lilly’s tirzepatide in China’s fast-growing market.
Outbound Deals
China’s $60B Out-Licensing Boom in 2025 Positions Biotech as Global Powerhouse in Oncology & Obesity
Chinese biopharmas may reach ~$60B in outbound deals by end-2025, led by Hengrui–GSK, 3SBio–Pfizer, XtalPi–DoveTree, and Hansoh–Regeneron. Oncology, obesity, and AI fuel China’s rise as a global licensing powerhouse, with top deals and trends highlighted.
H1 2025 earnings
H1 2025 Pharma Earnings: Key Takeaways from Chinese and Global Players
H1 2025 earnings show Chinese pharma entering a new growth phase, led by oncology innovation, biologics, and international licensing deals. Global pharma maintains steady expansion via obesity, diabetes, and oncology blockbusters.
semaglutide biosimilars
Semaglutide Mania in China: Inside the Biosimilar Gold Rush
China’s semaglutide market is heading toward $61B by 2032, unleashing a biosimilar frenzy. Over 25 drugmakers have filed 90+ applications, eight are nearing approval, and a pending patent ruling could trigger price wars that reshape diabetes and obesity care.
China online pharmacy
China Online Pharmacy Sales Break 700B Yuan, Semaglutide Surges 142% to Top
China’s online pharmacy sales hit ¥715B in 2024. Semaglutide surged 142%, overtaking sildenafil as the #1 product. Local players like Xingsha and Sunshine Mandi joined AstraZeneca, Novo Nordisk, and Pfizer among the top sellers
dulaglutide biosimilar
China Approves Boyouping® (BA5101), the World’s First Dulaglutide Biosimilar and First Domestic Product
China’s NMPA approved Boyouping® (BA5101), the world’s first dulaglutide biosimilar and first domestic product for type 2 diabetes. Developed by Boan Biotech and commercialized by Shanghai Pharma, Boyouping® matches Eli Lilly’s Trulicity® in efficacy and safety, with plans for global expansion.